Changyou Zhou

This inventor holds 45 USPTO granted patents and 2 published patent applications, plus 4 CIPO patents and 15 EPO patents, primarily in Cancer Treatment. Top assignees: Beigene, Ltd., Merck + Co., Inc., Merck Sharp + Dohme Corp.. Active years: 2002-2026.

USPTO Granted Patents = 45 (Patent Applications = 2)

% Patents Active = 71.1

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 15 (Patent Applications = 16)

Average Co-Inventor Count = 3.7

ph-index = 6

Forward Citations = 229(Granted Patents)

Location History:

Plainsboro, NJ (US) (2002 - 2010)
Beijing, CN (2015 - 2017)
Princeton, NJ (US) (2010 - 2022)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

4. 1 out of 22

Beigene Switzerland Gmbh

patents

5. 1 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

PARP Inhibitors

RAF Inhibitors

Indoleamine Inhibitors

Cancer Treatment

Kinase Inhibitors

Crystalline Forms

A2A Receptor Antagonists

B-RAF Kinase

Tricyclic Compounds

Bicyclic Compounds

Chemokine Receptor Modulators

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12582604 - Stable solid dispersion of a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor (2026-03-24),

2. 11534431 - Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer (2022-12-27),

3. 11472811 - Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist (2022-10-18),

4. 11472788 - Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases (2022-10-18),

5. 11202782 - Treatment cancers using a combination comprising PARP inhibitors (2021-12-21),

6. 10899763 - Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof (2021-01-26),

7. 10882856 - 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases (2021-01-05),

8. 10864203 - Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer (2020-12-15),

9. 10647714 - 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases (2020-05-12),

10. 10576087 - Fused tricyclic compounds as Raf kinase inhibitors (2020-03-03),

11. 10562899 - Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors (2020-02-18),

12. 10501467 - Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors (2019-12-10),

13. 10457680 - Process for preparing a PARP inhibitor, crystalline forms, and uses thereof (2019-10-29),

14. 10351559 - Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore (2019-07-16),

15. 10280163 - 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases (2019-05-07),

Title: Changyou Zhou: Pioneering Innovations in Cancer Treatment and Pharmaceutical Science

Introduction:

Changyou Zhou is a visionary inventor based in Princeton, NJ, whose passion for innovation and unwavering commitment to excellence have solidified his place as a pioneer in the realm of technology. With 44 patents under his belt, Zhou's groundbreaking work in cancer treatment and pharmaceutical science is reshaping the landscape of modern medicine.

Latest Patents:

Among his latest patents, Changyou Zhou has introduced a revolutionary pharmaceutical combination for combating cancer. This innovative approach involves a synergistic efficacy of a humanized antagonist monoclonal antibody against PD-1 and a RAF inhibitor, offering new possibilities for the prevention, delay of progression, and treatment of cancer. Additionally, Zhou has unveiled pyrazolotriazolopyrimidine derivatives as A2A receptor antagonists, showcasing his versatility and expertise in diverse areas of medical research.

Career Highlights:

Throughout his illustrious career, Changyou Zhou has made significant contributions to renowned companies such as BeiGene, Ltd. and Merck & Company, Inc. His innovative spirit and unparalleled dedication have led to the development of cutting-edge solutions that stand at the forefront of modern pharmaceutical advancements.

Collaborations:

Zhou's collaborative efforts with industry peers such as Lihu Yang and Hexiang Wang have further amplified the impact of his work, fostering a culture of innovation and knowledge-sharing within the scientific community. Through synergistic partnerships, Zhou continues to inspire the next generation of inventors to push the boundaries of what is deemed achievable in the realm of technology and medicine.

Conclusion:

In conclusion, Changyou Zhou's remarkable journey as an inventor epitomizes the essence of true pioneering spirit and relentless pursuit of excellence. His innovative patents, coupled with his collaborative approach and unwavering passion for pushing the limits of scientific discovery, underscore Zhou's transformative impact on the world of technology and pharmaceutical science. As a visionary in his field, Changyou Zhou serves as a beacon of inspiration for aspiring inventors worldwide, urging them to dream big and strive for greatness in their pursuit of innovation.